jetcityimage/iStock Editorial via Getty Images Eli Lilly ( NYSE: LLY ) and Organon ( NYSE: OGN ) have expanded their commercialization deal for migraine medicine Emgality (galcanezumab) in 11 additional markets. Organon will serve as the sole distributor and promoter for Emgality in Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the UAE. Emgality is a humanized monoclonal antibody indicated for the preventive treatment of migraine in adults, and in some markets, the indication specifies prophylaxis for those with at least four migraine days per month.
Total consideration to be paid to Lilly ( LLY ) for the expansion of territory includes an upfront payment of $22.5M as well as sales-based milestone payments. Organon ( OGN ) has been the sole distributor of Emgality in Europe since February 2024.
More on Eli Lilly, Organon, etc. Eli Lilly Q2 Earnings: Thanks To Tirzepatide, $1 Trillion Valuation Now In Sight Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis) Eli Lilly and Company (LLY) Q2 2024 Earnings Call Transcript Eli Lilly’s tirzepatide cuts risk of diabetes by 94% in obese patients U.S.
announces final drug prices after Medicare negotiations.
